Florien S. van Royen, Maarten van Smeden, Sander van Doorn, Patrick Souverein, Wouter A.C. van Amsterdam, Frans H. Rutten, James P. Sheppard, Geert-Jan Geersing
{"title":"Predicting deep venous thrombosis and pulmonary embolism in community patients with superficial venous thrombosis: a model development study","authors":"Florien S. van Royen, Maarten van Smeden, Sander van Doorn, Patrick Souverein, Wouter A.C. van Amsterdam, Frans H. Rutten, James P. Sheppard, Geert-Jan Geersing","doi":"10.1016/j.jtha.2026.06.036","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>In general practice, superficial venous thrombosis (SVT) is considered a benign condition that does not require anticoagulant treatment. However, a small but not insignificant subgroup of patients will develop serious thrombotic complications, such as deep venous thrombosis (DVT) and/or pulmonary embolism (PE). Tailored anticoagulant treatment in high-risk patients might prevent these complications, yet tools for clinical decision-making are currently lacking.</div></div><div><h3>Objectives</h3><div>To develop a multivariable prediction model to identify specific SVT subgroups at higher or lower risk of developing DVT/PE to aid clinical decision-making.</div></div><div><h3>Methods</h3><div>Data from general practices in the longitudinal routine care UK Clinical Practice Research Datalink Aurum database were used in this study, covering the period from 2000 to 2021. A multivariable prediction model was developed for adult SVT patients to predict the outcome of DVT and/or PE within 90 days after the first consultation for SVT. Prespecified predictors were biological sex, age, (history of) cancer, history of DVT/PE, and absence of varicose veins. The model’s performance was evaluated using bootstrapping and internal-external cross-validation.</div></div><div><h3>Results</h3><div>Of all identified patients with SVT (<em>N</em> = 293 166; median age, 61 years [IQR, 46-73]; 33% male), 10 301 (3.5%) developed DVT or PE within 90 days. The risk was highest in the first days after the SVT consultation: 51% of DVTs/PEs were diagnosed within 1 week, and 77% within 30 days. The C-statistic of the model was 0.66 (95% CI, 0.66-0.67), and the model showed good calibration (intercept = 0.04, slope = 1.01). High-risk patients with a predicted risk of ≥5% (9.7% of the total population) had a history of DVT/PE or were male with (a history of) cancer.</div></div><div><h3>Conclusion</h3><div>In community SVT patients, the average risk of DVT/PE development within 90 days of follow-up is 3.5%. This simple prediction model showed good performance in predicting the short-term risk of DVT/PE and could be used to rule out thrombotic complications in this setting, but also to identify a subgroup of patients at higher risk in whom further diagnostic testing for concomitant DVT/PE and/or short-term preventive anticoagulant treatment should be considered to prevent clot progression.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"24 10","pages":"Pages 3637-3646"},"PeriodicalIF":5.2000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538783626004228","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
In general practice, superficial venous thrombosis (SVT) is considered a benign condition that does not require anticoagulant treatment. However, a small but not insignificant subgroup of patients will develop serious thrombotic complications, such as deep venous thrombosis (DVT) and/or pulmonary embolism (PE). Tailored anticoagulant treatment in high-risk patients might prevent these complications, yet tools for clinical decision-making are currently lacking.
Objectives
To develop a multivariable prediction model to identify specific SVT subgroups at higher or lower risk of developing DVT/PE to aid clinical decision-making.
Methods
Data from general practices in the longitudinal routine care UK Clinical Practice Research Datalink Aurum database were used in this study, covering the period from 2000 to 2021. A multivariable prediction model was developed for adult SVT patients to predict the outcome of DVT and/or PE within 90 days after the first consultation for SVT. Prespecified predictors were biological sex, age, (history of) cancer, history of DVT/PE, and absence of varicose veins. The model’s performance was evaluated using bootstrapping and internal-external cross-validation.
Results
Of all identified patients with SVT (N = 293 166; median age, 61 years [IQR, 46-73]; 33% male), 10 301 (3.5%) developed DVT or PE within 90 days. The risk was highest in the first days after the SVT consultation: 51% of DVTs/PEs were diagnosed within 1 week, and 77% within 30 days. The C-statistic of the model was 0.66 (95% CI, 0.66-0.67), and the model showed good calibration (intercept = 0.04, slope = 1.01). High-risk patients with a predicted risk of ≥5% (9.7% of the total population) had a history of DVT/PE or were male with (a history of) cancer.
Conclusion
In community SVT patients, the average risk of DVT/PE development within 90 days of follow-up is 3.5%. This simple prediction model showed good performance in predicting the short-term risk of DVT/PE and could be used to rule out thrombotic complications in this setting, but also to identify a subgroup of patients at higher risk in whom further diagnostic testing for concomitant DVT/PE and/or short-term preventive anticoagulant treatment should be considered to prevent clot progression.
期刊介绍:
The Journal of Thrombosis and Haemostasis (JTH) serves as the official journal of the International Society on Thrombosis and Haemostasis. It is dedicated to advancing science related to thrombosis, bleeding disorders, and vascular biology through the dissemination and exchange of information and ideas within the global research community.
Types of Publications:
The journal publishes a variety of content, including:
Original research reports
State-of-the-art reviews
Brief reports
Case reports
Invited commentaries on publications in the Journal
Forum articles
Correspondence
Announcements
Scope of Contributions:
Editors invite contributions from both fundamental and clinical domains. These include:
Basic manuscripts on blood coagulation and fibrinolysis
Studies on proteins and reactions related to thrombosis and haemostasis
Research on blood platelets and their interactions with other biological systems, such as the vessel wall, blood cells, and invading organisms
Clinical manuscripts covering various topics including venous thrombosis, arterial disease, hemophilia, bleeding disorders, and platelet diseases
Clinical manuscripts may encompass etiology, diagnostics, prognosis, prevention, and treatment strategies.